Submission Deadline 10/11/2026
Fiscal Capacity $50,135,013
| Opportunity Number | RFA-MH-27-135 |
|---|---|
| Agency | HHS-NIH11 |
| Application Deadline | 10/11/2026 |
| Award Amount | $50,135,013 |
| Status | Posted |
| Sector | Health |
| Cost Sharing | Not Required |
Fiscal Parameters & Taxonomy
Authority HHS-NIH11
Status Posted
Who Can Apply
Public and State controlled institutions of higher education For profit organizations other than small businesses Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts City or township governments Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Special district governments County governments Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments
Eligibility Intelligence
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Program Description
The purpose of this notice of funding opportunity (NOFO) is to elucidate the key components of the therapeutic effects of rapid-acting psychotropic interventional drugs (RAPIDs) by addressing the methodological challenges involved with these clinical trials. In addition, this NOFO seeks to advance understanding of how RAPIDs and adjunctive psychosocial interventions can be optimally delivered, monitored, and sustained over time to enhance effectiveness and generalizability. The NOFO will support studies designed to enhance the rigor of RAPID clinical trial design, which will ultimately increase the interpretability of the data and the generalizability of the results.
CFDA Programs
93.242 Mental Health Research Grants
93.279 Drug Use and Addiction Research Programs
Agency Contact
Division of Translational Research DTRcommunications@nih.gov
✉ DTRcommunications@nih.gov📞 301-402-2541
Related Intelligence Guides
In-depth editorial guides covering this agency's programs, eligibility requirements, and application strategies.